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mune arthritis. Hypoxia-inducible factor-1a (HIF-1a) as a
transcription factor in response to hypoxia suggests that it
could be a potential therapeutic target for the treatment of
RA. In this study, we assessed whether the HIF pathway
blockade attenuates the manifestations of RA in the collagen-
induced arthritis (CIA) rat model. We constructed a short
hairpin RNA (shRNA) lentiviral expression vector targeting
HIF-1a (pLVX-shRNA-HIF-1a) and to achieve HIF-1a RNA
interference. Quantitative RT-PCR, immunoﬂuorescence
staining, and western blot were used to detect the expressions
of HIF-1a, vascular endothelial growth factor (VEGF), phso-
pho (p)-p65, and p-ILBɑmRNA and protein, respectively. Mi-
cro-computed tomography was used to investigate joint
morphology at different time points after CIA induction.
Moreover, enzyme-linked immunosorbent assay (ELISA) was
used to monitor the expression of inﬂammatory cytokines.
In vitro analyses revealed that pLVX-shRNA-HIF-1a effectively
inhibited the expression of HIF-1a and VEGF and led to the
activation of p-65 and p-ILBɑ, as well as decreased proinﬂam-
matory cytokine expression in cell culture. Inhibition of HIF-
1a in rats decreased signs of a systemic inﬂammatory condi-
tion, together with decreased pathological changes of RA.
Moreover, downregulation of HIF-1a expression markedly
reduced the synovitis and angiogenesis. In conclusion, we
have shown that pharmacological inhibition of HIF-1 may
improve the clinical manifestations of RA.Science, Shenzhen, Guangdong 518055, China.
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Rheumatoid arthritis (RA) is a chronic, progressive disorder that
is characterized by synovial tissue proliferation and joint inﬂamma-
tion, ultimately causing the destruction of articular cartilage and sub-
chondral bone.1–3 The current view is that inﬂammatory cytokines
play an essential role in the RA process, and the nuclear factor1330 Molecular Therapy: Nucleic Acids Vol. 19 March 2020 ª 2020
This is an open access article under the CC BY-NC-ND license (htkappa-B (NF-kB) signaling pathway is one of the most important
pathways included.4–6 Both tumor necrosis factor a (TNF-a) and
interleukin (IL)-1 are critical mediators of the inﬂammatory response
in RA. Clinical trials of anti-TNF-a/IL-1 reagents have demonstrated
the therapeutic efﬁcacy in cases of RA.2,7,8 There is growing evidence
supporting the notion that hypoxia is the critical effector for both in-
ﬂammatory and destructive responses in RA. It has been reported that
hypoxia is crucial for the development and persistence of RA in both
animals and humans.9,10
More recent research indicated that hypoxia, due to elevated oxygen
consumption by inﬁltrated myeloid cells, is the main feature of in-
ﬂamed tissue.11,12 The typical pathological symptoms of early-stage
RA are changed vascular density and increased neovascularization
and followed by chronic inﬂammation and bone destruction. In
this process, hypoxia acts as a major regulator of inﬂammatory medi-
ators.13 Hypoxia-inducible factor-1 (HIF-1) is a major mediator that
adapts to hypoxia. The HIF-1 heterodimer is composed of two helix-
loop-helix proteins, namely, HIF-1a and HIF-1b.14,15 HIF-1a is the
key transcriptional factor in a hypoxic response. Previous studies
have demonstrated that the synovium of patients with RA demon-
strates a hypoxic nature and presents HIF-1a upregulation.16,17tp://creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.orgUnder hypoxic conditions, HIF-1a is activated and stably expressed,
accumulates in the nucleus and then binds with other hypoxic
response elements to form a conformer.18 HIF-1a and the constitu-
tively expressed aryl hydrocarbon receptor nuclear translocator acti-
vate and migrate to the nucleus, where it binds to HIF-1b to form the
complex; the complex binds to hypoxia-responsive elements and
active hypoxia response genes that mainly mediate cell proliferation,
angiogenesis, and migration.13,19
In addition, HIF-1a activation is upregulated by a variety of inﬂam-
matory factors, such as, TNF-a, IL-1b, and IL-33, which are overex-
pressed in RA synovial ﬁbroblasts, but the underlying molecular
mechanism of action remains unclear.20,21 HIF-1a is activated, and
mass production-enhanced RA synovial ﬁbroblasts mediate the
expansion of inﬂammatory T cells, causing the further overexpression
of proinﬂammatory cytokines, such as interferon-g (IFN-g) and IL-
17.16,22 The above pathogenic mechanisms indicate a vicious cycle
that ultimately leads to severe RA development.
Lee et al.23 have silenced HIF-1a by short interfering RNA (siRNA) in
rheumatoid synovial ﬁbroblasts and found hypoxia in arthritic joints
may induce the differential expression of matrix metalloproteinase-1
(MMP-1) and MMP-13 in a HIF-1a-dependent manner in rheuma-
toid synovial ﬁbroblasts during joint inﬂammation. This indicates
that HIF-1a controls the genes in bone destruction in RA, which
can be used as an effective therapeutic target. siRNA interference
therapy is one of the more widely used gene therapy methods. In
this study, the exogenous short hairpin structure of the interfering
RNA (short hairpin RNA [shRNA]) fragment of HIF-1a was con-
structed on a lentiviral vector. Gene recombinant technology was
used to obtain lentivirus particles stably expressing HIF-la-shRNA
(pLVX-HIF-la-shRNA). The effect of lentivirus-mediated shRNA
on the target gene HIF-1a and its related genes was determined in
cell-based experiments. Animal experiments were also conducted to
evaluate the therapeutic efﬁcacy of our novel pLVX-HIF-la-shRNA
for RA.
RESULTS
HIF-1a and VEGF Expression Analysis In Vitro
The expression of HIF-1a and vascular endothelial growth factor
(VEGF) mRNA in the pLVX-shRNA-HIF-1a group was signiﬁcantly
(4.7- and 2.8-fold) lower than that in the collagen-induced arthritis
(CIA) synovial cells without transfection group (CSC) and
pLVX-shRNA-conHIF-1a groups (p < 0.01) (Figures 1A and 1B).
No statistical difference was found between the CSC and pLVX-
shRNA-conHIF-1a groups (Figures 1A and 1B). Western blot results
showed that the protein expression bands of HIF-1a and VEGF were
signiﬁcantly lower in the synovial cells of the pLVX-shRNA-HIF-1a
group than in those of the CSC and pLVX-shRNA-conHIF-1a groups
(Figure 1C). This indicates that pLVX-shRNA-HIF-1a can signiﬁ-
cantly silence target gene expression at the protein level. Further study
demonstrated that decreased inﬂammation in the pLVX-shRNA-
HIF-1a group was used as a marked activation of NF-kB signaling,
as detected by a remarkable reduction in phospho (p)-ILBɑ andp-NF-kB/p65 in the synovial cell (Figure 1D), indicating that the
loss of HIF-1amay inhibit joint inﬂammation and NF-kB activation.
The results of immunoﬂuorescence showed that the ﬂuorescence in-
tensity of HIF-1a and VEGF proteins was signiﬁcantly lower in the
pLVX-shRNA-recombinant (r)HIF-1a group than in the CSC and
the pLVX-shRNA-conHIF-1a groups (Figures 1E and 1F).
Cytokine Concentration in Cell Culture Supernatant and
Peripheral Blood Serum
Enzyme-linked immunosorbent assay (ELISA) detected related in-
ﬂammatory factors in cell culture supernatant and serum: TNF-a,
IL-1b, and IL-6. The concentrations of TNF-a in the cell culture su-
pernatant after virus infection were 2.6-fold in the CSC and 1.9-fold
in the pLVX-shRNA-HIF-1a groups lower than in the pLVX-
shRNA-conHIF-1a group (p < 0.01) (Figure 1G). The concentrations
of IL-1b in the cell culture supernatant after virus infection were 1.9-
fold in the CSC and 1.8-fold in the pLVX-shRNA-HIF-1a groups
lower than in the pLVX-shRNA-conHIF-1a group (p < 0.01) (Fig-
ure 1H). The concentrations of IL-6 in the cell culture supernatant af-
ter virus infection were 1.61-fold in the CSC and 1.3-fold in the
pLVX-shRNA-HIF-1a groups lower than in the pLVX-shRNA-con-
HIF-1a group (p < 0.01 and p < 0.05) (Figure 1I). In the inﬂammatory
factors in serum, at 7 and 14 days after treatment, results showed that
the expression of inﬂammatory factors TNF-a in the pLVX-shRNA-
HIF-1a group was 1.76-fold and 1.82-fold, reduced 7 days after
administration compared with the pLVX-shRNA-conHIF-1a and
phosphate-buffered saline (PBS) groups (p < 0.01) (Figure 1J). The
expression of inﬂammatory factors IL-1b in the pLVX-shRNA-
HIF-1a group was 2.10-fold and 2.13-fold reduced, 7 days after
administration, compared with the pLVX-shRNA-conHIF-1a and
PBS groups (p < 0.01) (Figure 1K). The expression of inﬂammatory
factors IL-6 in the pLVX-shRNA-HIF-1a group was 1.3-fold and
1.28-fold, reduced 7 days after administration, compared with the
pLVX-shRNA-conHIF-1a and PBS groups (p < 0.05) (Figure 1L).
The expression levels of TNF-a 1.83-fold and 1.84-fold decreased
in the pLVX-shRNA-HIF-1a group compared with the pLVX-
shRNA-conHIF-1a and the PBS groups at 14 days after administra-
tion (p < 0.01) (Figure 1J). The expression levels of IL-1b 1.76 -fold
and 1.79-fold decreased in the pLVX-shRNA-HIF-1a group
compared with the pLVX-shRNA-conHIF-1a and the PBS groups
at 14 days after administration (p < 0.01) (Figure 1K). The expression
of IL-6 in the pLVX-shRNA-HIF-1a group decreased after 14 days of
administration, but no statistical difference was found compared with
the pLVX-shRNA-conHIF-1a and the PBS groups (Figure 1L).
X-Ray and Micro-CT Measurement
Results showed that the entire joints of the pLVX-shRNA-conHIF-
1a and the PBS groups were severely damaged. The complete joint
structure was difﬁcult to observe, and the joint adhesion had no
obvious joint space. Joint destruction in the pLVX-shRNA-HIF-1a
group was suppressed, and joint structure and joint space were
clearly observed (Figure 2A). The X-ray scores of the pLVX-
shRNA-HIF-1a group were 2.27-fold and 2.33-fold lower than thoseMolecular Therapy: Nucleic Acids Vol. 19 March 2020 1331
Figure 1. Detection of Silencing Effect of pLVX-shRNA-Puro-HIF-1a on HIF-1a and VEGF Expression in a Synovial Cell
(A) HIF-1amRNA expression. (B) VEGF mRNA expression. (C) Western blot detection of HIF-1a and VEGF protein expression. (D) Western blot detection of p-p65 and p-ILBɑ
protein expression. Immunofluorescence detection of HIF-1a and VEGF expression in synoviocytes. (E) HIF-1a fluorescence expression. (F) VEGF fluorescence expression.
ELISA detects the concentration of related inflammatory factors. (G) The concentration of TNF-a in CIA synovial cell culture supernatant. (H) The concentration of IL-1b in CIA
synovial cell culture supernatant. (I) The concentration of IL-6 in CIA synovial cell culture supernatant. (J) The concentration of TNF-a in serum at 7 and 14 days after treatment. (K)
The concentration of IL-1b in serum at 7 and 14 days after treatment. (L) The concentration of IL-6 in serum at 7 and 14 days after treatment (*p < 0.05, **p < 0.01).
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Figure 2. X-Ray Analyses after 15 and 30 Days of Drug Administration to Assess Joint Destruction and Semiquantitative Integration Statistics
(A) Results of X-ray analyses. (B) X-ray semiquantitative analysis results.Micro-CT analysis joint structure scan and quantitative statistics. (C) 2D and 3D joint structure images.
(D) Bone mineral density (BMD). (E) The ratio of bone volume to tissue volume (BV/TV). (F) Trabecular number (Tb. N) (*p < 0.05, **p < 0.01, n = 5).
www.moleculartherapy.orgof the pLVX-shRNA-conHIF-1a and PBS groups 15 days after
treatment and 1.81-fold and 1.80-fold lower than those of the
pLVX-shRNA-conHIF-1a and PBS groups 30 days after treatment
(Figure 2B).Bone quality and quantitative analysis were performed by micro-
computed tomography (micro-CT) analysis, 15 and 30 days after treat-
ment. CT scans were performedwith 2D and 3D image reconstructions
using SkyScan analysis software. Joint destruction was clearly visible inMolecular Therapy: Nucleic Acids Vol. 19 March 2020 1333
Figure 3. Synovial Tissue Inflammation and Bone Destruction Observed by H&E Staining and Semiquantitative Analysis
(A) H&E staining. (B) H&E semiquantitative integral. (C) Articular cartilage toluidine blue staining detection (**p < 0.01, n = 5).
Molecular Therapy: Nucleic Acidsthe pLVX-shRNA-conHIF-1a and the PBS groups (Figure 2C). Quan-
titative analysis showed that bonemineral density (BMD)was 2.33-fold
and 3.03-fold reduced in the pLVX-shRNA-conHIF-1a and the PBS
groups compared with the pLVX-shRNA-HIF-1a group 15 days after
treatment and 1.95-fold and 2.25-fold reduced in the pLVX-shRNA-
conHIF-1a and the PBS groups compared with the pLVX-shRNA-
HIF-1a group 30 days after treatment (p < 0.05) (Figure 2D). Quanti-
tative analysis showed that bone volume to tissue volume (BV/TV) was
2.31-fold and 2.47-fold higher in the pLVX-shRNA-HIF-1a group
than in the pLVX-shRNA-conHIF-1a and the PBS groups 15 days after
treatment and 2.39-fold and 3.06-fold higher in the pLVX-shRNA-
HIF-1a group than in the pLVX-shRNA-conHIF-1a and the PBS
groups 30 days after treatment (p < 0.01) (Figure 2E). Quantitative
analysis showed that trabecular number (Tb. N) was 2.17-fold and
2.53-fold higher in the pLVX-shRNA-HIF-1a group than in the
pLVX-shRNA-conHIF-1a and the PBS groups 15 days after treatment1334 Molecular Therapy: Nucleic Acids Vol. 19 March 2020and 2.02-fold and 2.18-fold higher in the pLVX-shRNA-HIF-1a group
than in the pLVX-shRNA-conHIF-1a and the PBS groups 30 days after
treatment (p < 0.01) (Figure 2F).
Histological Analyses
The inﬂammatory cell inﬁltration in the articular cartilage surface as
well as the cartilage and subchondral bone destruction were severe in
the pLVX-ShRNA-conHIF-1a and PBS groups. However, the
destruction of articular cartilage and subchondral bone in the
pLVX-ShRNA-HIF-1a groupwas signiﬁcantly improved (Figure 3A).
Statistical integration showed that the hematoxylin and eosin (H&E)
score of the pLVX-shRNA-HIF-1a group was 1.82-fold and 1.80-fold
lower than that of the pLVX-shRNA-conHIF-1a and PBS groups
15 days after treatment and 1.72-fold and 1.69-fold lower than that
of the pLVX-shRNA-conHIF-1a and PBS groups 30 days after treat-
ment (p < 0.01) (Figure 3B).
Figure 4. Analysis of Osteoclasts and Pannus Staining and Quantitative Analysis in Joints
The red box is the enlarged region, and the red arrows are osteoclasts. (A) Tissue sections were stained with TRAP to examine osteoclast at different time points. (B) Statistical
data of osteoclast score in the fracture area of different groups (*p < 0.05, **p < 0.01, n = 5).
www.moleculartherapy.orgThe articular cartilage surface and the subchondral bone surface of the
pLVX-shRNA-conHIF-1a andPBS groupswere severely damaged. The
articular chondrocytes were hypertrophied, and the pathological fusion
between the joints was severe. Pathological damage of cartilage in the
pLVX-shRNA-HIF-1a group was signiﬁcantly improved (Figure 3C).
A large number of osteoclasts were present in the pLVX-shRNA-con-
HIF-1a and PBS groups, accompanied by a large number of pannus
formation. By contrast, the number of osteoclasts and the area of pan-
nus in the pLVX-shRNA-HIF-1a group signiﬁcantly improved (Fig-
ure 4A). Statistical integration showed that the osteoclast scores in thepLVX-shRNA-HIF-1a group were 1.21-fold and 1.25-fold lower than
those in the pLVX-shRNA-conHIF-1a and PBS groups at 15 days af-
ter treatment and 1.46-fold and 1.49-fold lower than those in the
pLVX-shRNA-conHIF-1a and PBS groups at 30 days after treatment
(Figure 4B).
Immunohistochemical Analysis of HIF-1a and VEGF Protein
Expression In Vivo
VEGF and HIF-1a were signiﬁcantly expressed in the synovial mem-
brane and bone-destruction sites of the pLVX-shRNA-conHIF-1a
and PBS groups compared with the pLVX-shRNA-HIF-1a groupMolecular Therapy: Nucleic Acids Vol. 19 March 2020 1335
Figure 5. Expression and Quantitative Analysis of HIF-1a and VEGF by Immunohistochemical Staining
(A) Immunohistochemical staining results of HIF-1a and VEGF. (B) HIF-1a immunohistochemical mean optical density (MOD) integration results. (C) VEGF immunohisto-
chemical MOD integration results (*p < 0.05, **p < 0.01, n = 5).
Molecular Therapy: Nucleic Acids(Figure 5A). The positive mean optical density (MOD) values of the
positive cells showed that the expression levels of HIF-1a were 2.97-
fold and 2.85-fold lower in the pLVX-shRNA-HIF-1a group than in
the pLVX-shRNA-conHIF-1a and PBS groups 15 days after treat-
ment and 3.01-fold and 2.54-fold lower in the pLVX-shRNA-HIF-
1a group than in the pLVX-shRNA-conHIF-1a and PBS groups
30 days after treatment (p < 0.01 and p < 0.05) (Figure 5B). The pos-
itive MOD values of the positive cells showed that the expression1336 Molecular Therapy: Nucleic Acids Vol. 19 March 2020levels of VEGF were 2.80-fold and 3.43-fold lower in the pLVX-
shRNA-HIF-1a group than in the pLVX-shRNA-conHIF-1a and
PBS groups 15 days after treatment and 3.36-fold and 3.41-fold lower
in the pLVX-shRNA-HIF-1a group than in the pLVX-shRNA-con-
HIF-1a and PBS groups 30 days after treatment (p < 0.01 and p <
0.05) (Figure 5C). In the expression levels of HIF-1a and VEGF, no
signiﬁcant differences were found between the pLVX-shRNA-HIF-
1a and normal animal groups (Figures 5B and 5C).
Figure 6. Multiscale Photoacoustic Imaging for
Neovascularization
(A) CIA rat model ankle-joint photoacoustic imaging. (B)
Semiquantitative analysis of relative light absorption in-
tensity (*p < 0.05, **p < 0.01, n = 5).
www.moleculartherapy.orgMultiscale Photoacoustic Imaging Angiogenesis Analysis
Multiscale photoacoustic (PA) imaging scans of the ankle joint were
evaluated 30 days after treatment. The angiogenic signal (red and yel-
low display in the Figure 6A) of the pLVX-shRNA-HIF-1a group was
lower than that of the pLVX-shRNA-conHIF-1a and PBS groups
(Figure 6A). Statistical semiquantitative analysis showed that the rela-
tive absorbance intensity of PA was 3.76-fold and 2.39-fold lower in
the pLVX-shRNA-HIF-1a group than in the pLVX-shRNA-conHIF-
1a and PBS groups 30 days after treatment (p < 0.01 and p < 0.05;
Figure 6B).Molecular ThDISCUSSION
The highly dysregulated architecture of the micro-
vasculature creates a hypoxia supply to the syno-
vium; activation of immune inﬂammatory cells
has been mediated by the proinﬂammatory signal
HIF-1a,24 so we hypothesized that silencing HIF-
1a plays a key role in the development of RA.
HIF-1a is regulated bymultiple factors at the tran-
scriptional and post-transcriptional levels and is a
complex process. RNA interference has been a
mature technology after years of development; it
can be used to silence the expression of any dis-
ease-related transcribed genomic sequence in a se-
lective and sequence-dependent manner.25,26
There is growing evidence supporting the notion
that synovial cells play important roles in both in-
ﬂammatory and destructive responses in RA.
As synovial cells have beendemonstrated topartic-
ipate in almost all of the pathological events and
play an important role in RA pathogenesis, we iso-
lated the synovial cells of CIA for in vitro-related
studies. RA synovial tissue natural hypoxia was
ﬁrst measured in the synovial ﬂuid sample of RA
patients by the Clark electrode in 1970.27 For a
further step, HIF-1a was found to play an impor-
tant role in the pathology of RA by regulating the
angiogenesis and expression of inﬂammatory fac-
tors.23,28,29 Moreover, Hollander et al.30 have
demonstrated HIF-1a stabilization in the RA joint
synovial tissue but not in nonarthritic synovia or in
most osteoarthritis (OA) synovia. Therefore, HIF-
1a plays a role of a potential therapeutic target for
the treatment of RA by using RNA interference.
In the pathogenesis of RA, changes in articular
cartilage are important characteristics. Thenormal articular cartilage tissue is transparent with a smooth sur-
face and is mainly composed of chondrocytes and cartilage matrix
without blood vessel and nerve structure inside.31,32 In addition,
the gap narrow is not obvious, and the amount of proliferation
of the articular surface is small.32 Long-term inﬂammation erodes
articular cartilage and subchondral bone, causing articular carti-
lage to become thin, sticky, and disrupted, whereas subchondral
bone is ﬁbrotic and causes osteoporosis. Multiple joints and tissues
are involved until the joint function is lost.33,34 In our research,
micro-CT and X-ray results showed that the joint destruction oferapy: Nucleic Acids Vol. 19 March 2020 1337
Molecular Therapy: Nucleic Acidsthe group with effective silencing of the target gene HIF-1a signif-
icantly improved, and the narrowing of the joint space was
controlled. The results of histological staining also showed that
the articular cartilage was severely damaged in the negative-treat-
ment group and control group, with a large number of pannus and
osteoclasts appearing in the subchondral bone. This condition
greatly improved after RNA interference treatment.
As we mentioned above, inﬂammation initially erodes the synovial
membrane around the joint and gradually leads to the destruction
of both cartilage and subchondral bone.35–37 At present, nonste-
roidal anti-inﬂammatory drugs (NSAIDs) and disease-modifying
anti-rheumatic drugs (DMARDs) are the ﬁrst choice for the ther-
apy of RA because they play a vital role in inhibiting inﬂammation
and controlling pathological progress.38,39 However, new thera-
peutic methods for the treatment of RA should be developed to
avoid the side effects of NSAIDs and DMARDs. With the develop-
ment of biotechnology and drug technology, increasing attention
has been paid to biotherapy agents that target genes, potentially
triggering human diseases. In the present study, we focused on
whether HIF-1a mediates inﬂammatory cell production and acti-
vation of inﬂammatory signals. We found that serum inﬂamma-
tory factor concentration, western blot detection of p-p65 and p-
ILBɑ protein expression, tartrate-resistant acid phosphate
(TRAP) staining, and H&E staining showed that the group with
effective silencing of the target gene HIF-1a demonstrated signif-
icantly reduced concentration of inﬂammatory factors and number
of osteoclasts, effectively inhibiting pathological development of
the CIA model.
Vascular growth is a typical feature in the inﬂammatory synovial tis-
sue of early and conﬁrmed RA.1,40,41 Angiogenesis is a complex pro-
cess that is affected by many factors, and VEGF is a key regulator of
angiogenesis during inﬂammation.42,43 VEGF is also a product of the
synovial membrane response to hypoxia and proinﬂammatory factors
invading the pathological environment.42,44,45 In our research, VEGF
immunohistochemical staining and multiscale PA vascular analysis
results showed that the group with effective silencing of the target
gene HIF-1a demonstrated signiﬁcantly reduced VEGF expression
and angiogenesis signals, which indicate the therapeutic effect of
RNA interference in another side as well.
In summary, pLVX-ShRNA-HIF-1a screened by in vitro cells can
effectively silence the target gene HIF-1a. The pharmacological ef-
fects of pLVX-ShRNA-HIF-1a on the rat CIA model were deter-
mined. Results indicated that pLVX-ShRNA-HIF-1a can effectively
inhibit inﬂammation protein expression and vascular proliferation
and signiﬁcantly improve the destruction of articular cartilage and
subchondral bone in CIA rats. These results indicate that HIF-1a
can be used as a target for the regulation of angiogenesis and the po-
tential treatment of RA. The potential clinical translation of this
method still needs a long time to process. Also, to determine whether
it is effective in the clinic, a nonhuman primate animal model is
needed.1338 Molecular Therapy: Nucleic Acids Vol. 19 March 2020MATERIALS AND METHODS
Animals
Fifty femaleWistar rats, 10 weeks of age, were purchased from Beijing
Vital River Laboratory Animal Technology (Beijing, China). The an-
imals were fed in a speciﬁc pathogen-free facility at the Shenzhen
Institute of Advanced Technology, Chinese Academy of Science.
The experimental protocol was approved by the Laboratory Animal
Ethical and Welfare Committee of the Shenzhen Institute of
Advanced Technology, Chinese Academy of Science (no: SIAT-
IRB-170302-YGS-A0285).Construction of si-HIF-1a Plasmid
Rat HIF-1a mRNA (GenBank: NM_024359) was employed as the
template strand, and an online shRNA design tool was used to
obtain the target gene interference sequence (http://rnaidesigner.
thermoﬁsher.com/rnaiexpress/sort.do). In this study, we designed
three HIF-1a target sequences to construct the lentiviral shRNAs
and negative sequence selected as a control (Supplemental Methods).
shRNA fragments were synthesized by Invitrogen (Shanghai, China),
and an Xhol cleavage site was inserted at the 30 end of shRNA. The
targeting sequence synthesizes two complementary nucleic acid
strands and was cloned into the target vector pLVX/U6/Green
ﬂuorescent protein (GFP). Then, they were conﬁrmed by speciﬁc
enzyme digestion and agarose gel electrophoresis by sequencing nu-
cleic acids (Figures S1 and S2). The correct vector plasmid packaging
virus was identiﬁed. The lentiviral shRNA-expressing plasmids
pLVX-shRNA2-puro, Amp+ (Biowit Technology, Shenzhen, China)
were transfected with the packaging plasmids into 293T cells for lenti-
virus generation (Figure S3). The viral supernatants were harvested,
and 293T cells were used to determine the titer of viral biological ac-
tivity. The titers of the lentiviruses were generally up to 108 transduc-
tion units (TU)/mL (Figure S4).Induction of Collagen-Induced Arthritis (CIA) in Wistar Rats and
shRNA Treatment Regiment
Forty rats were immunized to induce arthritis with collagen type II
(20022; Chondrex; dissolved in 0.05 M acetic acid) and incomplete
Freund’s adjuvant (IFA; 7002; Chondrex). The method was followed
as per the Brand et al.46 publication. Rats were observed three times a
week by the same experimenter to determine the presence of arthritis
and were identiﬁed as CIA when erythema and swelling were obvi-
ously observed, at least on the digits and/or paws.
Fifty rats were used in this study. Arthritis was present in 34 of 40
immunized rats 14 days after secondary immunization. After the
onset of arthritis, the rats were divided into four groups (n = 10) as
follows: an shRNA interference plasmid group (pLVX-shRNA-HIF-
1a), a negative control shRNA plasmid group (pLVX-shRNA-con-
HIF-1a), a PBS group, and normal rats as the control group.
In vitro experiments were screened for effective lentiviral vector
mediated with shRNA virus (concentration of 1  108 TU/mL)
and injected into the knee-joint and ankle-joint cavity of the CIA
model animal. Two injections each with a dose of 0.1 mL were
www.moleculartherapy.orgadministered per week for 2 weeks. The same method of operation
was performed in the other control group. After the administration
was ﬁnished, ﬁve rats in each group were selected for each efﬁcacy in-
dex test at 15 and 30 days.
Cell Culture and shRNA Infection
The synovial cells were isolated according to the previous studies.
Brieﬂy, immediately after euthanasia, the synovial tissue was ex-
tracted from the knee of the CIA model and placed in sterile
phosphate buffered saline (PBS). Synovial tissues were cut into
1- to 2-mm3 pieces (specimens were soaked in PBS throughout the
procedure). The shredded tissue pieces were transferred to a
35-mm-diameter Petri dish. A 4-mL volume of 0.4% type I collage-
nase (Sigma) was added to the Petri dish and was digested in a 5%
CO2 clean incubator at 37C for 4 h. Then, the tissue was ﬁltered
and centrifuged to obtain synovial cells. The cells were continuously
cultured in the incubator for 24 h, the adherent cells were primary
synovial cells, and the unattached cells were discarded. The cells
were placed in DMEM containing 10% fetal bovine serum and then
incubated.
CIA synovial cells were maintained in DMEM and plated into six-well
plates at 1  106 cells/well. Cells were assigned into the following
groups: CSC, transfected with shRNA interference plasmid group
(pLVX-shRNA-HIF-1a), and transfected negative control shRNA
plasmid group (pLVX-shRNA-conHIF-1a). After 24 h, the cells
were infected with viral supernatant (50 mL, 108 TU/mL) in the pres-
ence of polybrene (8 mg/mL ﬁnal concentrations) for 24 h at a multi-
plicity of infection (MOI) of 20 and then added to a fresh DMEMme-
dium. After 48 h, the cells were collected and stored under suitable
conditions for later experiments.
For ELISA detection of the inﬂammatory cytokines in the cell culture
supernatant, CIA synovial cells were maintained in DMEM and were
plated into 6-well plates at 1  106 cells/well. 24 h later, 10 ng/mL
TNF-a was added and incubated for another 4 h (the CSC group
does not add TNF-a). After that, the medium was discarded and
washed 2–3 times with PBS. Then, the cells were infected with super-
natants, as described above. After 48 h, the cell supernatants were
collected for ELISA (Neobioscience Technology, China).
Real-Time PCR Analysis
Total cell RNA was extracted using the Invitrogen RNA puriﬁca-
tion kit in accordance with the manufacturer’s instructions.
Real-time PCR reactions were performed in a LightCycler 96 sys-
tem (Bio-Rad). Reaction cycle conditions were as follows: 50C for
2 min and 95C for 10 min of predenaturation conditions, 40 cy-
cles at 95C for 15 s and 60C for 20 s and 72C for 30 s. The
primer sequences of the HIF-1a gene were as follows: forward
primer, 50-GTGGATATGTCTGGGTTGAG-30; reverse primer,
50-TTCTGTTTGTTGAAGGGAGA-30; the product was 140 bp.
The primer sequences of the VEGF were as follows: forward
primer, 50-TGTGAGCCTTGTTCAGAGCG-30; reverse primer,
50-GACGGTGACGATGGTGGTGT-30; the product was 252 bp.The primer sequences of the b-actin standard control gene were
as follows: forward primer, 50-CGTTGACATCCGTAAAGACC
TC-30; reverse primer, 50-TAGGAGCCAGGGCAGTAATCT-30.
Western Blot Analysis
Radioimmunoprecipitation assay (RIPA) lysis and extraction buffer
(Thermo Scientiﬁc; number 8900) were used to extract the total pro-
tein of CIA synovial cells. The same amount of protein was used to
load and incubate the sample in a blocking solution for 1 h after elec-
trophoresis to test HIF-1a, VEGF, phopsho-p65 (p-p65), phopsho-
ILBɑ (p-ILBɑ), and b-actin protein. Protein samples were separated
by 10% SDS-PAGE and transferred onto nitrocellulose membranes.
The membranes were blocked with 5% nonfat milk overnight at
4C, incubated with Tris-buffered saline/Tween 20 (TBST)-diluted
primary antibodies (HIF-1a antibody: 1:800, ab1; VEGF antibody:
1:800, ab46154; p-p65 antibody: 1:600, ab97726; b-actin antibody:
1:2,000, ab20272 [Abcam, Cambridge, MA, USA]; p-ILBɑ antibody:
1:200, GTX32224 [Gene Tex]) at room temperature for 2 h, and then
washed three times on the shaker for 10 min each time. The mem-
branes were then incubated with secondary antibodies (1:2,500,
ab6728; Abcam, Cambridge, MA, USA) at room temperature for
1 h and then washed three times with TBST on the shaker for
10 min each time. The test was purchased using a commercial
enhanced chemiluminescence (ECL) luminescence kit (Nanjing Jian-
cheng Bioengineering Institute, China; w028-2).
Immunofluorescence Analysis
CIA synovial cells were cultured on glass coverslips, washed with PBS
two times, and then ﬁxed with 4% paraformaldehyde in PBS. The cells
were then incubated with 3% bovine serum albumin blocking solu-
tion for 30 min at room temperature. The cells were stained with
HIF-1a (1:1,000) and VEGF (1:500) antibodies overnight at 4C
and then incubated with ﬂuorescein isothiocyanate (FITC)-conju-
gated secondary antibodies (1:1,000; Abcam, Cambridge, MA, USA;
ab150117 and 150115) for 40 min at room temperature. After
washing three times with PBS for 5 min each time, the nuclei were
stained for 10 min with the ﬂuorescent dye 40,6-diamidino-2-phenyl-
indole dihydrochloride (Sigma). The staining results were examined
by confocal laser-scanning ﬂuorescence microscopy (Leica, Germany;
TCS SP5).
ELISA
Blood was collected at days 7 and 14 postinjection. Serum and cell cul-
ture supernatant collected in front of inﬂammatory factors, such as
TNF-a, IL-1b, and IL-6, were detected using ELISA (Neobioscience
Technology, China), in accordance with the manufacturer’s
instruction.
X-Ray Assessment
The radiological test (35 kV, 20 s; Faxitron, X-ray) was completed
to evaluate the treatment effects of shRNA at days 15 and 30 postinjec-
tion. The semiquantitative integral analysis criteria are as follows:47 0 =
normal joint structure and clearance; 1 = joint space is suspected to be
narrowed, and the joint surface is slightly eroded; 2 = signiﬁcantlyMolecular Therapy: Nucleic Acids Vol. 19 March 2020 1339
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joint space, partial erosion of subchondral bone, and mild deformity of
the articular surface; 4 = unrecognized joint space, most of the cartilage
of the subchondral bone, and obvious structural abnormalities; and 5 =
the entire joint contour is blurred, severely deformed, and accompanied
by physical disability. All indicators of the scores were tested by two
different experimenters, and the average of the two was the ﬁnal result.
Micro-CT Analyses
At different time points (days 15 and 30) after treatment, micro-CT
measurement was performed on the knee joint by using a model
1076 scanner (SkyScan, Bruker, Belgium). The detection parameter
was 18 mm resolution, Al 1.0 mm ﬁlter, 60 kV voltages, and 400 mA
current. The ratio of BV/TV, Tb. N, and BMD bone-related parame-
ters were detected for all the samples.
Histological Staining Analyses
The rats were killed by overdosing with pentobarbital sodium. All
samples were ﬁxed in cold paraformaldehyde solution (4%) for
24 h and decalciﬁed in 0.5 M EDTA neutral solution at room temper-
ature for 45 days. Knee-joint parafﬁn sections (7 mm) were stained us-
ing an H&E staining kit (Nanjing Jancheng Technology). Toluidine
blue (TB) staining was performed in accordance with to the manufac-
turer’s instructions (Beijing Leagene Biotech). The criteria for semi-
quantitative evaluation of H&E are as follows:48,49 0 = normal joint
synovial tissue and bone structure; 1 = synovial cell hypertrophy
and inﬂammatory cell erosion of synovial tissue; 2 = cartilage destruc-
tion and pannus present; 3 = most articular cartilage and subchondral
bone are destroyed; 4 = joint adhesions and stiffness and accompa-
nying disability.
TRAP staining (Sigma) was performed to detect the expression of os-
teoclasts in accordance with the manufacturer’s instructions. Semi-
quantitative analysis of TRAP staining was conducted in accordance
with the following integral criteria:48 0 = no osteoclasts appeared; 1 =
found a small amount of osteoclasts (lining fewer than 5% of most
affected bone surfaces); 2 = a plurality of osteoclasts present in the
ﬁeld of view (lining 5%–25% of most affected bone surfaces); 3 = a
large number of osteoclasts are present in the ﬁeld of view (lining
30%–50% of most affected bone surfaces); and 4 = large-scale osteo-
clasts appear in the ﬁeld of view (lining >50% of most affected bone
surfaces). The scoring was completed by two experimenters, and
the average was calculated. Above histologically stained sections
were randomly selected for each rat, and six different views were
observed for each section.
Immunohistochemical Analyses
Immunohistochemical staining for HIF-1a and VEGF proteins was
completed. Samples were ﬁxed in cold paraformaldehyde solution,
decalciﬁed, dehydrated, and then embedded in parafﬁn. The sections
were subjected to antigen retrieval in boiling 1% citrate buffer for
15 min and then incubated with 0.3% hydrogen peroxide for
10 min to block endogenous peroxidase activity. The sections were
incubated with protein block buffer at room temperature for1340 Molecular Therapy: Nucleic Acids Vol. 19 March 202010 min to block nonspeciﬁc background staining. The sections were
incubated with anti-HIF-1a antibody (1:500; Abcam, Cambridge,
MA, USA; ab1) or anti-VEGF antibody (1:800; Abcam, Cambridge,
MA, USA; ab46154) and then with biotinylated secondary antibody
before illuminating in accordance with the manufacturer’s instruc-
tions (Abcam; ab80436). The MOD was calculated to analyze the
semiquantitative expression of HIF-1a and VEGF using Image-Pro
plus 6.0 software. Two slices were randomly selected from each rat
with six different areas as the detection ﬁeld of view.
PA Analyses
PAanalyses were completed 30 days after treatment. Ratswere anesthe-
tized with 1% sodium pentobarbital, and the hair around the bare joint
was removed. An ultrasound and PA system (Vevo LAZR; FUJIFILM
VisualSonic, Toronto, Ontario, Canada) were employed to acquire a
vascular proliferative signal. A linear array transducer (LZ-400,
30 Hz) was utilized to obtain spatially coregistered ultrasound and
PA. Light generated by a tunable laser operating at 808 nm for PA
was delivered through ﬁber-optic bundles integrated into the trans-
ducer. The acquisition parameters, such as the gains of 28 dB for ultra-
sound images and 40dB for PA,were constant for all of the imaging ses-
sions. The MOD was calculated to analyze semiquantitatively the
relative absorbance intensity of PA using Image-Pro plus 6.0 software.
Statistical Analysis
Data were statistically analyzed using one-way ANOVA SPSS 17.0
software to calculate p values. Results were expressed as mean ± stan-
dard deviation (SD), and statistical signiﬁcance was considered at p <
0.05 (signiﬁcant) and p < 0.01 (highly signiﬁcant).
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